KRAS G12D Inhibitor LY3962673

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12D, with potential antineoplastic activity. Upon oral administration, KRAS G12D inhibitor LY3962673 specifically targets and noncovalently binds to KRAS G12D. This prevents KRAS G12D-mediated signaling and activation of downstream survival pathways. This leads to an inhibition of the growth of tumor cells that overexpress KRAS G12D. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, invasion, and metastasis. LY3962673 has a higher affinity binding to the GDP-bound conformation of KRAS G12D compared to the GTP-bound form.

**Synonyms:** - KRAS G12D-mutant Inhibitor LY3962673 - LY 3962673 - LY-3962673 - LY3962673